Phase I/II Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma
Latest Information Update: 28 Sep 2020
At a glance
- Drugs YS 110 (Primary) ; Antihistamines; Corticosteroid; Paracetamol
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 23 Sep 2020 Status changed from active, no longer recruiting to completed.
- 29 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2017 New trial record